Author response for "Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activations to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies"
Author response for "Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activations to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies" is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Author response for "Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activations to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies" have?
Author response for "Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activations to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies" has 0 citations in the OpenAlex counts ScholarIQ stores.
When was Author response for "Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activations to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies" published?
Author response for "Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activations to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies" has 2019 year in the ScholarIQ index.
What is the open-access status of Author response for "Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activations to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies"?
Author response for "Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activations to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies" has closed oa status in the ScholarIQ index.
What is the DOI of Author response for "Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activations to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies"?
The DOI for Author response for "Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activations to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies" is on the source record.
What is the OpenAlex record for Author response for "Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activations to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies"?
The OpenAlex for Author response for "Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activations to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies" is on the source record.